CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4 Grant or award Director acquired 11,700 shares (grant or award)
- 4 Grant or award Chief R&D Officer acquired 40,150 shares (grant or award)
- 4 Grant or award SVP & Chief Accounting Officer acquired 14,900 shares (grant or award)
- 4 Grant or award President & CEO acquired 94,100 shares (grant or award)
- 4 Grant or award SVP, COO & CFO acquired 40,150 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award SVP & Chief Commercial Officer acquired 200,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief R&D Officer sold 3,960 shares at $17.97 ($71,161)
- 4 Open-market sale SVP & Chief Accounting Officer sold 2,713 shares at $17.97 ($48,753)
- 4 Open-market sale President & CEO sold 13,556 shares at $17.97 ($243,601)
- 4 Open-market sale SVP, COO & CFO sold 8,863 shares at $17.97 ($159,268)
- 4 Open-market sale SVP, COO & CFO sold 25,000 shares at $19.79 ($494,750)
- 4 Open-market sale President & CEO sold 100,000 shares at an average $17.37 ($1,737,090)
- 4 Open-market sale SVP, COO & CFO sold 25,000 shares at $15.83 ($395,750)
- 4 Open-market sale Director sold 3,000 shares at $17.84 ($53,520)
- 4 Grant or award Chief R&D Officer acquired 75,000 shares (grant or award)
- 4 Grant or award SVP, COO & CFO acquired 75,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 2,375 shares at $18.06 ($42,893)
Page 13 of 49 · 970 filings